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Abstract 
INTRODUCTION: Peptide vaccines offer anti-tumor efficacy with very low toxicity. However, 
repeat stimulation with an immunogenic peptide leads to activation induced cell death (AICD), 
decreasing efficacy. We engineered variants of an immunogenic peptide (E39) and tested their 
ability to induce a robust, sustainable immune response.  
METHODS: Multiple variants of E39 were created by exchanging 1 or 2 amino acids. We tested the 
PBMC proliferation, cytokine production and cytolytic activity induced by each variant peptide.  
RESULTS: Repeated stimulation with E39 likely led to in vitro AICD, while stimulation with E39’ led 
to T-cell proliferation with less evidence of AICD, modest cytokine production and high CTL 
activity.  
CONCLUSIONS: E39’ appears to be the optimal variant of E39 for inducing effective long-term 
immunity. 
Key words: Folate binding protein, folate receptor alpha, J65, E39, E39’. 
Introduction 
Treatment of cancer has significantly expanded 
beyond the traditional management strategies of 
chemotherapy, radiation, and surgery, with 
immunotherapy becoming increasingly important. 
Within this field, there is considerable interest in 
developing strategies for prevention of cancer 
recurrence after standard of care treatment using 
therapies that induce adaptive immunity against a 
specific tumor-associated antigen (TAA). We have 
previously published our successful attempts to 
induce such a response to a well-known TAA, HER2, 
using immunogenic epitopes, specifically E75 and 
GP2. These peptides form the basis of vaccines that 
strive to stimulate production of cytotoxic T 
lymphocytes (CTLs) that are specific to the antigen 
and, thus, capable of targeted lysis of tumor cells.[1-5] 
In addition to an initial production of CTLs, memory 
T cells are produced, which maintain immune 
surveillance and offer the promise of prolonged 
disease-free survival when these vaccines are given in 
the adjuvant setting.[6,7] With our most successful 
peptide vaccine, NeuVax, now in a phase III trial for 
FDA approval, the identification of additional TAAs 








Folate binding protein (FBP), also known as 
folate receptor alpha, is a near ideal TAA for 
immunotherapy. FBP is over-expressed in over 90% of 
ovarian and 20-50% of breast cancers, yet is rarely 
expressed in normal tissues [8]. Analogous to HER2 in 
breast cancer, the level of FBP expression has been 
found to be greater than 20-fold higher in malignant 
cells compared to normal cells, and its 
over-expression is linked to more aggressive 
cancers.[3] Not only is FBP expression increased in 
cancer cells, it is also inherently immunogenic; it has 
been recognized by CTLs isolated from ovarian and 
breast cancer patients and shown to induce 
tumor-specific cytokine release and cytolysis [4-9]. 
While the body of literature studying FBP-directed 
immunotherapies is limited, the combination of 
frequent over-expression in cancer cells, correlation 
with aggressive disease, and natural immunogenicity 
make FBP an attractive TAA for use in peptide 
vaccines. 
 We have previously shown that FBP peptides 
were recognized by HLA-A2+ ovarian and breast 
tumor associated lymphocytes that were not 
previously subjected to in vitro antigen stimulation.[4] 
Upon further investigation, E39 (FBP191-199, 
EIWTHSYKV) was the most consistently recognized 
of these HLA-A2 restricted antigenic epitopes within 
the FBP.[6] Furthermore, E39-stimulated TALs from 
ovarian cancer patients recognized allogeneic, 
HLA-A2 positive, FBP-expressing ovarian cancer cells 
and induced cell lysis of these and other 
FBP-expressing epithelial tumor cells of the colon and 
pancreas.[4] Knowing the potential of E39 to function 
as an immunodominant epitope, we are conducting a 
phase I/IIa trial, in which HLA-A2 positive patients 
are given varying doses of E39 with GM-CSF. At the 
time of interim analysis, the vaccine was very well 
tolerated and induced a strong, dose-dependent 
immune response. Early efficacy results showed a 
statistically significant increase in estimated 2-year 
DFS for patients receiving an optimal dose of the 
vaccine over controls and patients receiving lower 
doses [10]. 
Given our success with peptide vaccines and 
promising early results with E39, we anticipate future 
trials to better assess its clinical efficacy. There are 
growing concerns, however, that repeated stimulation 
with one immunogenic peptide, such as E39, may 
actually impair immune memory, which is the 
ultimate goal of any peptide vaccine. Although the 
exact mechanisms are not fully understood, this 
overstimulation seems to adversely affect CTL 
selection and proliferation. It has been shown that 
peptide stimulation produces a polyclonal CTL 
response, with only some of these CTL populations 
becoming the effector and memory CTLs necessary 
for effective long-term immune surveillance. 
Over-stimulation with an immunogenic peptide may 
lead to activation induced cell death (AICD) of these 
highly desired cells [11]. If this process is repeated 
with continued stimulation, it can lead to weaker 
responses each time. A strategy of inoculating 
patients with an attenuated peptide has been 
proposed as a way to minimize this risk of AICD, but 
the effect on T cell selection and expansion is 
unknown. Our early work with the new E39 peptide 
affords us the opportunity to test these theories. 
To this end, we engineered multiple attenuated 
peptides by substituting one or two amino acids of the 
wild-type peptide, E39. We then tested the attenuated 
peptides for in vitro immunologic responses. Our 
hypothesis was that these attenuated peptides, once 
bound to the HLA molecule, would lead to altered 
interactions with the T cell receptor (TCR) and 
ultimately to proliferation of different populations of 
CTLs. In this report, we describe the identification of 
E39’ as the ideal attenuated version of E39 through 
discovery of its in vitro potential as a primer of a 
robust, sustainable immune response against FBP. 
Methods 
Peptide Creation 
Multiple variants of the E39 peptide were 
produced by exchanging one or two amino acids; 
these peptides and their amino acid sequence are 
displayed in Table 1. DNAStar software predicted that 
reducing the positive charge of the amino acid in 
position 5 and removing the phenolic structure at 
position 7 would improve the flexibility of residues 
5-9 and allow for a better fitting of the TCR with the 
peptide-MHC complex. Specifically, the flexibility of 
the peptide is improved by reducing the positive 
charge at the amino acid in position 5 (histidine) 
through replacement with phenylalanine. 
Phenylalanine is not charged and its benzene 
aromatic ring is a close substitution for the imidazole 
ring of histidine. Then, the phenolic structure of 
tyrosine was replaced with the aliphatic core chain of 
threonine. Both tyrosine and threonine contain a 
hydroxyl side chain group. Thus, the positive charge 
in position 5 and the rigid structure in position 7 were 
eliminated in the creation of E39’ by changing 
histidine to phenylalanine at position 5 and tyrosine 
to threonine at position 7. J77 and J78 each had only 
one of these key substitutions. The remaining 
peptides were created with variations on these two 
changes, some with additional substitutions at 
position 1 designed to alter the HLA binding. An 
Applied Biosystems Model 430A peptide synthesizer 




used solid-phase synthesis to produce the epitopic 
peptides. 
 
Table 1. E39 variant peptides and amino acid sequences. 












T2 Stabilization Assay 
To evaluate the HLA-A2 binding strength of 
each peptide, cell line T2 cells were cultured overnight 
in RPMI 1640 medium in the presence of saturating 
quantities (100µg/ml) of a single variant peptide (J78 , 
J77 , E39’ , J64 , J63 , J66 , J67 or J68). The cells were 
then stained with a monoclonal antibody, BB7.2, used 
to recognize the bound, HLA-A2 molecule. The level 
of expression of the peptide-bound HLA-A2 complex 
was measured by the average fluorescent intensity, 
the mean channel fluorescence (MCF), using flow 
cytometry.  
In vitro Immune Monitoring 
Peripheral Blood Mononuclear Cells (PBMCs) 
were isolated from multiple healthy donors, 
separated into the plastic-adherent and non-adherent 
fractions. The different fractions were then prepared 
as described below. The non-adherent fraction 
contained 95% CD3 positive cells. The 
plastic-adherent PBMCs were cultured in complete 
RPMI 1640 medium containing 10% Fetal Calf Serum 
(FCS), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), and IL-4 for 5 days. These cell 
cultures resulted in immature monocyte-derived 
dendritic cells (iDCs). Plastic-adherent and 
non-adherent PBMCs were stored frozen in liquid 
nitrogen until use.  
The PBMCs were primed with the E39 or a 
variant peptide; first with 500,000 iDCs plated in 24 
1.0 ml well plates with complete RPMI medium and 
allowed to attach for 2-3 hours. The complete RPMI 
medium was removed and replaced with serum-free 
RPMI medium. Peptides were added to the wells for a 
final concentration of 10µg/ml. One ml RPMI 1640 
medium containing 20% FCS was added to the wells. 
After 2 hours of incubation at 37C, 3 × 106 of 
non-adherent fresh PBMCs were added. IL-12 (100 
pg/m) was added after two additional hours of 
incubation. Then, IL-2 was added to a final 
concentration of 150 IU/ml, 24-36 hours later. Cells 
were maintained in culture for 7 days in the presence 
of 100 IU/ml of exogenous IL-2. Thereafter, cells were 
washed, rested for 24 hours in complete RPMI 
medium without IL-2. This procedure was repeated 
for a total of 3 weekly priming sessions for each 
peptide.  
Cell Proliferation  
PBMC cultures from six different healthy or 
naïve, HLA-A2-positive donors were primed with a 
single dose of E39 or an attenuated E39 variant (J77, 
J78, E39’) weekly as described above. The total 
number of cells was counted after a week in culture 
and just prior to the next week’s priming.  
Interleukin-2 (IL-2) Production 
Those peptides able to effectively stimulate 
PBMC proliferation (J77, E39’) were then tested for the 
ability to stimulate IL-2 production as compared to 
E39 and a control. PBMCs were primed weekly for 
three weeks with either a control of no protein (NP), 
E39, J77, or E39’ in the previously described method. 
For three days after the third priming, IL-2 
concentrations were measured in supernatant.  
Interferon-γ (IFN-γ) Release Assay  
Next, the amount of IFN-γ produced was 
assessed following PBMC stimulation with different 
methods. PBMCs from healthy donors were primed 
once a week for three weeks with E39’ or E39 as 
described above. The PBMCs stimulated with E39’ 
were then targeted against T2 cells loaded with E39, 
J77, or E39’. PBMCs primed with E39 were only tested 
against cells loaded with E39. IFN-γ release into the 
supernatant of each set of PBMC cultures was 
measured over two days. 
Cytotoxicity Assays 
Finally, PBMC cultures were tested for their 
ability to lyse cells loaded with FBP peptides. Primed 
PBMCs were targeted against 51Chromium labeled, T2 
cells loaded with three concentrations (0, 5, 25 µg/ml) 
of the appropriate peptide. The percent lysis was 
calculated by the amount of free 51Chromium in 
supernatant as measured after 5 hours. The PBMC 
were primed and the T2 cells loaded in the same 
fashion as the IFN-γ assays; E39’-primed cells were 
tested against T2 cells loaded with E39, E39’, or J77, 
while E39-primed PBMCs were tested only against 
E39. 
 





T2 Stabilization Assay 
All of the variant peptides were able to bind the 
HLA-A2 molecule as indicated by a MCF greater than 
the control (Figure 1). As expected, peptides with a 
substitution at position 1 (J63, J64, J66 and J68) 
demonstrated high affinity for the HLA-A2 molecule 
(198, 199, 186, and 202 MCF, respectively). Those 
peptides did not undergo further investigation as 
their higher affinity for the HLA-A2 molecule was not 
consistent with the goal of an attenuated peptide. 
Peptides created with only substitutions in positions 5 
and 7 (E39’, J77 and J78) were all able to bind the 
HLA-A2 molecule. J78’s affinity for HLA-A2 did not 
differ significantly from that of E39 (127 v 125 MCF). 
J77 and E39’ had much weaker binding, with 78 and 
65 MCF, respectively.  
 
 
Figure 1. HLA-A2 stabilization of E39-derived attenuated epitopes 
 
 In vitro Immune Monitoring 
Cell Proliferation 
The PBMC proliferation potential of E39’, J77, 
and J78 was measured over six cultures from multiple 
different, healthy, HLA-A2 positive donors; 
representative data from two of these donors are 
shown in Figures 2 and 3, respectively. Figure 2 shows a 
representative graph of cell counts one week after 
each of three weekly stimulations. In this case, E39 
and E39’ resulted in the highest expansion to 11.9 x106 
cells and the increase continued to four weeks with 
both peptides. J77 and J78 did not invoke improved 
cell proliferation compared to NP. In Figure 3, PBMC 
proliferation from another donor that underwent 
similar priming is shown, but the data instead 
represent cell counts 7 to 14 days after the third 
priming with each respective peptide. Cells primed 
with E39’ continued to proliferate from 6.1 x106 to 9.1 
x106 cells between 7 to 14 days. Conversely, PBMCs 
primed with the highly immunogenic E39 underwent 
the opposite response with decrease cell counts 
between days 7 and 14, likely representing AICD. The 
J77 and J78 primed PBMCs had a similar, low-level 
response in this patient with expansion to 6.5 x106 and 
6.8 x106 cells, respectively. Because J78 did not exhibit 
a consistent ability to induce PBMC proliferation, it 
was precluded from further studies. 
 
 
Figure 2. PBMC proliferation after stimulation with E39 or E39 derived 
epitopes; Donor #1.  
 
Figure 3. PBMC proliferation after stimulation with E39 or E39 derived 
epitopes; Donor #2.  
 
IL-2 Production 
IL-2 production was measured for E39 and the 
attenuated peptides that consistently resulted in 
PBMC proliferation (E39’ and J77; Figure 4). At three 
days out from the third stimulation with J77, there 
was no increase in IL-2 production. In response to 
both E39 and E39’ priming, however, there was a 
significant increase in IL-2. Importantly, stimulation 
with E39’ produced less IL-2 than E39 (611 and 844 
pg/ml, respectively). Because J77 primed PBMCs did 
not produce IL-2, it was precluded from further 
testing except as a target peptide of for E39 and 
E39’-primed PBMCs. 




Interferon-γ Release Assay 
The IFN-γ release after priming with E39 and 
E39’ was measured as described above and is 
displayed in Figure 5. E39’-primed cells recognized all 
FBP peptide variants on re-stimulation with 
peptide-loaded T2 cells as evidence by initial IFN-γ 
release. Those E39’-primed PBMCs re-stimulated with 
E39’ had the smallest response; 48% and 0% from 
baseline on days 1 and 2, respectively. The 
E39’-primed PBMCs stimulated with J77 had a small, 
yet stable response with a 57% and 43% increase from 
baseline on days 1 and 2, respectively. The 
E39’-primed, E39-stimulated (E39’, E39) population 
maintained a stable, moderate response with a 99% 
and 102% increased from baseline on day 1 and 2. The 
highest IFN-γ release was seen in E39-primed PBMCs 
targeted against E39-loaded T2 cells, with an increase 
of 184% from baseline on days 1 and 2. 
 
 
Figure 4. Interleukin 2 (IL-2) levels produced by PBMCs after third priming 
with E39’ E39, and J77. 
 
Figure 5. IFN-γ levels in PBMCs after three weekly stimulations with E39’ or 
E39, followed by a fourth re-stimulation with either E39’, E39, or J77. 
 
Cytotoxicity Assays 
The percent specific lysis of peptide-loaded T2 
cells produced by the combinations described above 
is displayed in Figure 6. As expected, loading cells 
with 0 µg/ml concentration of peptides produced no 
response in all sequences. E39’-primed PBMCs 
recognized and lysed T2 cells loaded with all FBP 
variants. The lowest response occurred when 
targeting J77-loaded cells (4.2 and 8.2% at 5 and 25 
µg/ml). The other two populations of E39’-primed 
cells showed impressive cytotoxicity, with 24.5% and 
17.4% lysis of E39-loaded cells and 20.9% and 23.2% of 
E39’-loaded cells at 5 and 25 µg/ml, respectively. The 
E39-primed PBMCs targeted at E39 did not perform 
as well as these two groups of E39’-primed cells. 
E39-primed cells lysed only 11.1% and 14.6% of 
E39-loaded T2 cells at 5 and 25 µg/ml, respectively. 
 
 
Figure 6. % specific lysis of CTLs after three weekly E39’ or E39 priming doses 




In this study of variant peptides created from 
E39, we found that the candidate peptides, J78, J77 
and E39’, were able to stably bind the HLA-A2 
molecule. When these peptides were tested for the 
ability to induce PBMC proliferation, E39’ consistently 
showed the best results, particularly over multiple, 
repeated T cell stimulations. Interestingly, while E39 
induced a robust initial proliferation, some 
populations of cells contracted after continued 
priming with E39, indicating significant AICD. We 
then tested cells primed with E39 and E39’ for 
functionality finding that cells primed by E39 
produced high amounts of IL-2 and IFN-γ, while 
those primed by E39’ made more moderate amounts 
of each cytokine. Lastly, E39’-primed cells showed 
excellent cytotoxicity when targeted to both E39 and 
E39’ loaded T2 cells, and actually performed better 
than cells primed with the wild type peptide, E39. 
Cumulatively, these findings suggest that an 
attenuated version of a strong T cell epitope can help 
preserve the lytic CTLs in repeatedly stimulated T cell 
populations.  
While there have been great strides made toward 
the goal of a successful peptide vaccines able to 




induce a long-term, adaptive anti-tumor response, the 
final goal is yet to be reached. Multiple investigators 
have been able to induce anti-tumor T cell responses 
ex vivo, but clinical responses are often disappointing. 
Part of the reason for these disappointing results 
seems to be early elimination of the final effectors of 
these vaccines, the peptide-specific CTL capable of 
tumor lysis.[12] There is concern that the repeated 
stimulation with a strongly immunogenic peptide is 
actually inducing AICD. A new strategy of 
inoculating patients with a weaker or attenuated 
version of a specific peptide has the potential to avoid 
this issue.  
With this strategy in mind, we set out to produce 
an attenuated version of E39, a known immunogenic 
peptide, and test the immune response it would 
induce as compared to E39. Multiple novel peptides 
were created, with three potential candidates that 
possessed altered amino acids within the TCR binding 
site. These three peptides were all shown to bind the 
HLA-A2 molecule. Next, we tested how these 
peptides would stimulate PBMC proliferation, 
particularly through multiple rounds of stimulation. 
E39’ consistently performed better than any other 
attenuated peptide and nearly as well as E39 at initial 
stimulation (Figure 2). The more interesting finding, 
however, was noted after watching continued 
proliferation two weeks after a third priming (Figure 
3). Here, E39-induced PBMC proliferation fell off 
significantly in the second week, while cells primed 
by E39’continued to expand in number This graphic is 
representative of similar findings from additional 
PBMC populations tested in this study and is a 
common phenomenon observed with repeated 
stimulation with one, immunogenic peptide. The late 
drop-off of PBMCs likely corresponds to the very 
AICD suspected following continual stimulation with 
E39. The proliferation shown with E39’, however, is 
very encouraging and indicates that the attenuated 
peptide did not induce AICD, perhaps by avoiding 
over-stimulation.  
While this proliferation data was encouraging, 
further testing was needed to determine the 
functionality of the induced T cell populations. To test 
this, we first measured cytokine production after 
PBMC stimulation with E39 and E39’. E39’ resulted in 
blunted cytokine production as compared to E39, as 
demonstrated in assays of IL-2 and IFN-γ production. 
These higher cytokine levels in response to E39 may 
simply occur because E39 is a stronger signal to T 
cells, but may also be related to selection of certain T 
cell populations after repeated stimulation. 
While E39’ led to less AICD, it was unclear how 
the reduced binding affinity and cytokine response 
would alter the ability to mediate tumor cell death. 
The CTL response that is induced by a pathogen or by 
an immunogenic peptide is understood to be 
polyclonal, with some cells differentiating to produce 
cytokines and others, the effector cells, to perform cell 
lysis. Even within the effector cells, there are 
short-lived effector cells and memory precursor 
effector cells.[13] The differentiation, proliferation and 
apoptosis of these varying T cell populations are 
controlled by a complex interplay of cytokines and 
interactions between the TCR and the peptide-HLA 
complex. While this process is not fully understood, 
cells with high affinity TCRs seem to be the most 
effective at lysing target cells and are most likely to 
become memory T cells.[11,14] Thus, the ability to 
induce these high TCR affinity T cells specific for the 
target TAA is key to the success of peptide vaccines. 
High levels of IFN-γ have been linked to a weaker 
TCR signal caused by low affinity of the TCR to the 
HLA-peptide complex and this weak TCR signal has 
been shown to lead to early contraction of effector 
CTL populations.[14,15] Similarly, while IL-2 is 
needed for CTL proliferation, high levels have been 
linked to production of regulatory T cells that may 
hinder effective clearance of targeted cancer cells. 
Multiple, strong stimulations with E39 may, 
theoretically, have led to AICD of highly cytolytic 
effector CTLs and instead selected for T cells that 
focus more on cytokine production, accounting for the 
high levels of IFN-γ and IL-2.  
The cytolytic assays demonstrated that 
E39’-primed cells were capable of lysing cancer cells 
loaded with any of the three FBP peptides tested. 
These cells performed best when targeting cells 
loaded with E39’, but they were also able to lyse a 
high number of cells loaded with E39. More 
importantly, these E39’-primed cells had higher 
peptide-specific cell lysis than E39-primed cells. After 
over-stimulation with E39, the apoptosis 
demonstrated by the PBMC proliferation tests seems 
to have affected mainly effector CTLs, leaving behind 
cell populations with low TCR affinity that produce 
high levels of IL-2 and IFN-γ release, but have 
decreased CTL activity. Less potent stimulation with 
E39’, on the other hand, did not seem to induce the 
same degree of effector CTL AICD, maintaining 
populations of CTLs with high TCR affinity. This is 
ideal, as these cells are thought to not only be effective 
at target cell lysis, but are also thought to become 
memory T cells. 
 
 





Figure 7. Proposed mechanism of improved T cell response after repeated stimulation with attenuated peptide (E39’) and parent peptide (E39). 
 
 
Figure 8. Phase I/2a trial design in breast and ovarian cancer (NCT02019524)16 
 
The findings of this trial support the theory that 
stimulation with an attenuated peptide, E39’, could 
lead to a more effective cancer vaccine (as depicted in 
Figure 7). Whether this peptide will be most effective 
alone or in combination with the more 
immunodominant parent peptide, E39, will be the 
focus of our next trial. We have started a Phase Ib trial 
in breast and ovarian cancer patients with 
FBP-expressing tumors. The trial design incorporates 
three arms for the primary vaccine series consisting of 




six inoculations: one arm with all inncoulations being 
E39, another with the first three inoculations with E39 
followed by three with E39’, and the last with E39’ 
given first, followed by E39. Once patients have 
completed their primary vaccine series, their residual 
immunity will be measured in vivo and in vitro and 
they will be classified as significant responders or 
non-responders. Patients will then be randomized 
again to receive either E39 or E39’ in a four arm 
booster series (Figure 8). The primary objectives are to 
determine the most effective method to maximize 
short-term and long-term FBP-specific immunity, to 
determine the most effective booster inoculations to 
maintain FBP-specific immunity, and to evaluate the 
safety of the vaccination series. This currently 
enrolling study (NCT02019524) will allow us to use 
different sequences of the wild type peptide (E39) and 
attenuated peptide (E39’) in order to answer these 
novel and important research questions in the field of 
immunotherapy.[16] If successful, the application of 
this novel strategy using a native peptide in 
combination with an attenuated version could be 
far-reaching.  
Conclusion 
In summary, these experiments demonstrate that 
repeated stimulation with highly immunogenic E39 
likely leads to AICD of T cells populations in vitro 
including peptide-specific effector CTLs with high 
affinity TCRs. E39’ appears to be the optimal variant 
of E39 as it consistently results in T cell proliferation, 
stimulates T cells to produce modest cytokines and, 
most importantly, selects for effector CTLs with high 
TCR affinity that are necessary for tumor cell lysis. 
The potential of this version of E39 to induce an 
enduring, cytolytic anti-FBP immune response that 
results in tumor cell lysis is currently being evaluated 
in a phase Ib clinical trial in ovarian and breast cancer 
patients. 
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